Effectiveness of Interfaces Program to Promote Work Ability of People With Disabilities

June 23, 2021 updated by: Navah Ratzon, Tel Aviv University

Evaluating the Effectiveness of "The Interfaces Program" to Promote Person's Components, Performance and Improving the Work Environment of People With Disabilities

the objectives of the study is to Evaluate the effectiveness of "The Interfaces Program" to promote person's components, performance and improving the work environment of people with disabilities.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

People with disabilities experience many barriers in trying to integrate into the competitive market. The barriers may be result of the unique characteristics of the individual (characteristics of the disability, occupational history, work self-efficacy, etc.), the characteristics of the occupation and occupational performance (characteristics of the job and the job demands) and environmental barriers (accessibility, discrimination, stigma and lack of opportunities, etc.). The main response to the integration problems of people with disabilities in the world of work is supported employment service. Supported employment focuses primarily on placement of the individual and do not relate to barriers relating to the individual's ability to develop a career.

The present study examines the effectiveness of a new intervention program "The interfaces program " aiming to promote career development process among people with disabilities working in the competitive market. The program presents an integration of the Person-Environment-Occupation-Performance (PEOP) model and lead career development theories. The ultimate goal of this study is to examine the effectiveness of the "interfaces program" by examining its impact on the promotion of objective and subjective measures among people with disabilities who work and receive supported employment services.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
84

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
    • Isarel
      • Tel Aviv, Isarel, Israel, 6936468
        • Maya Huber

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

21 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • psychiatric or physical disability
  • 12 years of educations minimum
  • at least 26 score on the Montreal cognitive assessment ( MOCA)
  • working at least 3 month in the open market

Exclusion Criteria:

  • autistic spectrum disorder (ASD)
  • Developmental Cognitive Disability
  • alcohol or drags comorbidities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: experimental
The "interfaces Program"
Behavioral: The Interfaces Program
career development program
Active Comparator: control group
supported employment using the individual placement and support (IPS) model
Behavioral: IPS
supported employment using the individual placement and support (IPS) model

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
proactive behavior Questionnaire (developed for this study)
Time Frame: A change in proactive behavior measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
proactive behavior during the last week
A change in proactive behavior measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
Adult subjective assessment of participation (ASAP)
Time Frame: A change in subjective experience of participation measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
subjective experience of participation in meaningful occupations
A change in subjective experience of participation measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
Work Behavior Inventory (WBI)
Time Frame: A change in work behavior measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
employer assessment of work behavior and work performance
A change in work behavior measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
work self efficacy Questionnaire (WSS-37)
Time Frame: A change in work self efficacy measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
subjective report of work self efficacy
A change in work self efficacy measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
health perception sf 12 Questionnaire Health Perception
Time Frame: A change in health perception measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
subjective report of health perception
A change in health perception measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
career self management - subjective self management perception Questionnaire - developed for this study
Time Frame: A change in career self management measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
subjective report of career self management
A change in career self management measure will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
perception of environmental work barriers - subjective work barriers perception Questionnaire - developed for this study
Time Frame: A change in perception of environmental barriers will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention
subjective perception of environmental work barriers
A change in perception of environmental barriers will appear after 9 sessions over 3 month (4 first meeting will be done once a week, and 5 meetings once in two weeks) of intervention, and after 3 month form the end of the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Tel Aviv University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Laszlo Tauber Family Foundation

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: navah ratzon, prof, Tel Aviv University
  • Principal Investigator: Rachel Gali cinamonp, prof, Tel Aviv University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2016

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2018

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 29, 2017

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 15, 2018

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 16, 2018

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 24, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 23, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Maya Huber
  • Principal Investigator (Prof) (Other Identifier: TelAvivU)
  • Principal Investigator (Other Identifier: TelAvivU)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Disabilities Mental

Clinical Trials on The Interfaces Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings